Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. by Smyth, Bobby P et al.
O
rig
in
al
 p
ap
er
 Assessment of hepatitis C infection in 
injecting drug users attending an addiction 
treatment clinic 
BP Smyth1, E Keenan2, JJ O’Connor3 
Academic Unit1, Young Persons Centre, 79 Liverpool Rd, Chester, 
The Drug Treatment Centre2, Pearse St, Dublin, The Drug Treatment Centre3, 
Pearse St, Dublin. 
Abstract 
Background Injecting drug users represent a high risk group for hepatitis C (HCV) 
infection. Currently, screening of this group for HCV is inconsistently implemented. 
Aim We designed a HCV assessment algorithm and sought to determine the frequency 
with which injecting drug users completed the assessment process. 
Methods Prospective study of a HCV assessment algorithm in the setting of a specialist 
outpatient addiction treatment clinic. Participants consisted of consecutive new attenders 
over a six-month period with a history of injecting. 
Results Only 21 (18%) of 119 patients reached a satisfactory endpoint of assessment. 
Forty-eight injectors were tested for antibody to HCV, of whom 26 (54%) tested positive. 
Thirteen of those with positive test results were no longer attending when the test result 
became available. Only four of the 19 patients who were referred, attended the on-site 
hepatology clinic. 
Conclusions Thorough screening of injecting drug users for HCV within one treatment 
service is difficult. There is a need for explicit policies on this issue involving co-
operation between primary care providers and addiction services and hepatology 
services. (Ir J Med Sci 2000; 169:129-132) 
Introduction 
Among the difficulties encountered in the investigation and treatment of hepatitis C is the high 
default rate by patients.1-4 Ryan studied individuals who became aware that they were hepatitis C 
antibody positive following blood donation.5 All were counselled regarding the implications of 
this result at the transfusion centre and advised to contact their GP to arrange referral to specialist 
hepatology services. 
 At follow-up, specialist referral had occurred in only 60% of cases. In the specialist 
hepatology clinic setting, Foster found that 33% of patients with newly diagnosed hepatitis C did 
not attend following referral and injecting drug users were over-represented within the group of 
This article is a reproduction of that published in:  Irish Journal of Medical Science, 169(2), pp. 129-132.  Pagination 
may not match that of the original. 
non-attenders.’ There are no reports on audit of the screening and assessment of injecting drug 
users for hepatitis C in the setting of an addiction treatment clinic. 
 We designed a HCV assessment algorithm and sought to determine the frequency with 
which injecting drug users completed the assessment process. 
Method 
Setting 
An assessment process for hepatitis C was established in the Drug Treatment Centre at Trinity 
Court, Dublin, (see algorithm). All attenders with a history of injecting drug use were counselled 
regarding hepatitis C and encouraged to consent to testing. There were no clear national or 
international guidelines on the best form and content of such pre-test counselling for hepatitis C. 
 We modelled the counselling approach on that already in use for HIV pre-test counselling.6 
This involved discussing the test procedure, the implications of both a positive and a negative 
result and highlighting the need for specialist follow-up in case of positive test results. A serum 
sample was obtained for analysis, and this usually occurred during the second week of methadone 
treatment. Those who were no longer attending when the test result became available were 
requested to reattend by letter. All patients who tested positive for antibody to hepatitis C were 
advised to accept referral to a hepatologist. Attendance was facilitated by providing initial 
assessment with a hepatologist within Trinity Court and appointment waiting times were 
generally less than one week. 
 The most frequent treatment programme offered to new attenders who were opiate 
dependent was a brief (21 day) methadone detoxification. During treatment, patients were 
required to give frequent urine samples to monitor for ongoing drug misuse. Those patients who 
continued to use opiates during detoxification were usually discharged from the treatment 
programme. Research indicates that only 20-30% of drug users successfully complete outpatient 
methadone detoxification.7 
Hepatitis C Assessment 
 A short form was designed for the purposes of this prospective study and baseline 
information was completed by the doctor performing the initial patient interview. All new 
attenders between 1st August 1996 and 31st January 1997 were included if they had a history of 
injecting drug use. Testing was considered not to be indicated in those reporting a previous 
positive test result and in those reporting a negative test result in the preceding six months. The 
screening test used was a third generation enzyme linked immunosorbent assay for antibody to 
hepatitis C virus. 
 Positive tests were confirmed via an additional assay. The audit form was kept with the 
patient’s clinical notes and updated as the patient progressed through the assessment process. 
Each patient was followed for six months or until they reached an end-point in the assessment 
algorithm, whichever was the shorter. To ensure completeness of information, the clinical notes 
of all 397 new attenders were examined at the end of the study. 
Statistical analysis 
The dichotomous outcome variable examined was successful completion of the assessment 
process by reaching a satisfactory end-point. The association between successful completion and 
gender, employment status and referral source was examined by Pearson’s chi squared rest or 
Fisher’s exact test as appropriate. Odds ratios and their 95% confidence intervals were calculated. 
Associations with age and length of injecting history were examined via Student’s r test. 
Results 
There were 138 patients with a history of injecting drug use who first attended during the study 
period. Our cohort consisted of the 119 for whom hepatitis C testing was currently indicated (see 
algorithm). Seventy-one per cent were male and 92% were unemployed. The mean age was 22.8 
years (range 15 to 37 years) and the mean interval since first injecting was 21 months. All 
patients injected opiates primarily. Only 12 % were referred by their own GP. 
 Five (4%) individuals were unwilling to have a test. Only 48 (47%) of those who agreed to 
testing actually had the test. Fifty-one of the 54 who were not tested after consenting, defaulted 
from their drug treatment programme prematurely. Of the 48 tested, 26 (54%) were positive for 
hepatitis C antibody. Thirteen of those with positive test results were no longer attending the 
clinic when the result became available. 
 The 21 (18%) patients who reached a satisfactory end-point of our screening process 
included 16 who were informed of a negative test result, four who attended the on-site hepatology 
clinic and one who chose to be referred to a hepatology clinic elsewhere. (We were not able to 
confirm that this last patient attended the other hepatology clinic.) 
 Females tended to be more likely to complete the assessment (odds ratio 2.1, 95% 
confidence interval 0.8-5.5). No other independent variable was significantly associated with an 
increased likelihood of completing assessment. 
Discussion 
The finding that only 19 (14%) injecting drug users were aware of their hepatitis C status when 
first attending the addiction treatment service indicates that this high risk group are not being 
successfully screened elsewhere. Compliance with assessment and treatment of chronic illnesses, 
which are symptomatically silent, is poor.” Although this population is young and unlikely to 
encounter significant morbidity for many years, early diagnosis of hepatitis C, and subsequent 
monitoring, should ideally occur.1,9 
 Gordon has argued that screening of targeted populations, such as drug users, is likely to be 
cost effective.10 In England the cost of screening has been estimated at Stg£l25 per drug user.11 If 
individuals were aware of being hepatitis C positive they might be less inclined to pass on 
injecting equipment to others. Also they would have the option of curtailing their alcohol 
consumption, as it is known that moderate to heavy alcohol use accelerates progression to 
cirrhosis in chronic hepatitis C.12 The relatively small numbers involved in this study restricted 
our ability to detect factors significantly associated with completion of the assessment process. 
There was a trend for females to be more likely to complete assessment. 
 The chronic relapsing nature of opiate dependence suggests that many patients will 
recommence this assessment process during subsequent attendance. The failure of many to 
complete assessment may be due to a poor understanding by injectors of the implications of 
hepatitis C.13 There should he increased emphasis on education regarding hepatitis C during the 
attendance at treatment services. 
 The primary goal of Trinity Court is to assist individuals in their attempts to cease illicit 
drug use. Medical assessment of illnesses such as HIV and HCV represent secondary roles and 
are offered to drug users while attending for addiction treatment. Defaulting from addiction 
treatment emerged as the principal reason for individuals to drop out of their HCV assessment. 
Almost half of those who dropped out immediately after consenting to HCV testing did not even 
commence their methadone detoxification. Many others commenced but did not complete the 
brief detoxification. 
 Premature cessation of addiction treatment also hampered communication of test results to 
many drug users. Although letters were posted to all individuals with positive test results 
requesting their reattendance, six did not reattend to be informed of the rest result. As most drug 
users self-refer, a letter to the GP was nor considered appropriate. However, this problem could 
be partially overcome in the future if self-referrers were encouraged to provide consent for 
addiction centres to communicate the outcome of medical investigations to GPs. The HCV 
assessment process could also be facilitated by earlier testing during addiction treatment. Many 
addiction services offer a substantially longer period of methadone treatment during 
detoxification. This may prolong contact with treatment centres and help complete the hepatitis C 
assessment. 
 Among hepatitis C positive injecting drug users, Foster found that 55% attended their 
initial hepatology assessment appointment. In this study, we found that only four of 19 patients 
attended the on-site liver clinic. The reason for this is very unclear. There is a reluctance to 
initiate treatment of hepatitis C where individuals continue to misuse opiates. Awareness of this 
fact by drug users may cause them to decide to postpone medical investigation and treatment. 
 The assessment of hepatitis C places additional demands on the resources of health 
services dealing with injecting drug users. This study identifies the difficulties in completing this 
assessment. Many injecting drug users have regular contact with a general practitioner, and 
increased numbers could 
 
 
 
 
  
 
undergo assessment in the primary care setting.14,15 However, in the USA, Shehab found that GPs 
demonstrated “considerable confusion about the use of hepatitis C tests and the effectiveness of 
treatment”.16 There is a need for explicit policies regarding screening, co-ordinated between 
primary care providers and addiction treatment centres and hepatology services. 
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